SYN-Tech Chem & Pharm Co Ltd (1777) - Total Liabilities
Based on the latest financial reports, SYN-Tech Chem & Pharm Co Ltd (1777) has total liabilities worth NT$369.57 Million TWD (≈ $11.64 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SYN-Tech Chem & Pharm Co Ltd net asset momentum to track the company's year-over-year net asset growth rate.
SYN-Tech Chem & Pharm Co Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how SYN-Tech Chem & Pharm Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See SYN-Tech Chem & Pharm Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
SYN-Tech Chem & Pharm Co Ltd Competitors by Total Liabilities
The table below lists competitors of SYN-Tech Chem & Pharm Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Alpha Astika Akinita S.A
AT:ASTAK
|
Greece | €15.83 Million |
|
Nicola Mining Inc
V:NIM
|
Canada | CA$17.60 Million |
|
Konya Kagit Sanayi ve Ticaret AS
IS:KONKA
|
Turkey | TL1.19 Billion |
|
Sagittarius Life Science
TWO:3205
|
Taiwan | NT$26.91 Million |
|
Marks and Spencer Group PLC
LSE:MKS
|
UK | GBX6.89 Billion |
|
Synergy Green Industries Limited
NSE:SGIL
|
India | Rs2.91 Billion |
|
Suraj Estate Developers Ltd.
NSE:SURAJEST
|
India | Rs10.31 Billion |
|
Fabryki Mebli Forte S.A.
WAR:FTE
|
Poland | zł428.75 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down SYN-Tech Chem & Pharm Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SYN-Tech Chem & Pharm Co Ltd (1777) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.03 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.14 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.12 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SYN-Tech Chem & Pharm Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SYN-Tech Chem & Pharm Co Ltd (2015–2025)
The table below shows the annual total liabilities of SYN-Tech Chem & Pharm Co Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$369.57 Million ≈ $11.64 Million |
+26.72% |
| 2024-12-31 | NT$291.65 Million ≈ $9.19 Million |
-50.02% |
| 2023-12-31 | NT$583.48 Million ≈ $18.38 Million |
+0.58% |
| 2022-12-31 | NT$580.13 Million ≈ $18.28 Million |
-36.37% |
| 2021-12-31 | NT$911.71 Million ≈ $28.72 Million |
+68.38% |
| 2020-12-31 | NT$541.46 Million ≈ $17.06 Million |
-22.75% |
| 2019-12-31 | NT$700.89 Million ≈ $22.08 Million |
-3.44% |
| 2018-12-31 | NT$725.85 Million ≈ $22.87 Million |
+29.70% |
| 2017-12-31 | NT$559.62 Million ≈ $17.63 Million |
+115.30% |
| 2016-12-31 | NT$259.92 Million ≈ $8.19 Million |
+1.88% |
| 2015-12-31 | NT$255.12 Million ≈ $8.04 Million |
-- |
About SYN-Tech Chem & Pharm Co Ltd
SYN-TECH Chem. & Pharm. Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) in Taiwan, Asia, Europe, the Americas, and internationally. The company offers test drugs and surfactants, as well as various Chinese, Western, and animal medicines. It also provides products in various categories, such as anticoagulant, attention deficit hyperactivity disorder, skeletal muscle relax… Read more